pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
ABBVIE · news · pharmadog
← back to ABBVIE
News mentioning ABBVIE
74
stories
1d
Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: Analysts
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
11 companies hiring in New Jersey
biospace
1d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
2d
Merck and Sarah Cannon team up to boost oncology trial efficiency
fiercebiotech
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
9d
AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinois
endpoints
9d
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
stat
10d
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
biopharma dive
10d
STAT+: Pharmalittle: We’re reading about a Sanofi drug shortage, a Jazz Pharma deal, and more
stat
10d
MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial
fiercebiotech
10d
Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex
fiercebiotech
11d
As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
biospace
13d
STAT+: Up and down the ladder: The latest comings and goings
stat
13d
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
stat
13d
Is the biotech capital of the world moving?
stat
14d
STAT+: Medicare quietly gave blockbuster AbbVie drug seven extra years before price negotiations, advocacy group asserts
stat
14d
BioVie shares halve on murky Parkinson’s disease readout
biospace
14d
The top 12 companies hiring in biopharma now
biospace
15d
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
16d
4 potential biotech M&A targets, plus a pretty sure bet from J&J
biospace
18d
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
20d
AbbVie touts strong momentum for Skyrizi despite rising competition
endpoints
20d
AbbVie shares pressured as Q2 I&I beat falls below investor expectations
biospace
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
21d
J&J secures right to take the helm in up to $925M Sail CAR T pact
biospace
22d
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
fiercebiotech
22d
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
fiercebiotech
23d
Oak Hill takes SPAC track to Nasdaq with Roche asset in tow
biospace
23d
Incyte ditches phase 1-stage JAK inhibitor to pursue next-gen options
fiercebiotech
← prev
page 1 of 3
next →
